As it prepares regulatory filings for anidulafungin and dalbavancin, Vicuron Pharmaceuticals Inc. priced a public offering worth $70.8 million in gross proceeds. (BioWorld Today)
In what its CEO called the most significant transaction in the history of the company, Nastech Pharmaceutical Co. Inc. formed a potential $346 million global alliance with Merck & Co. Inc. to develop and commercialize Peptide YY 3-36 Nasal Spray (PYY) for obesity. (BioWorld Today)
Vion Pharmaceuticals Inc. decided to move one lead cancer drug into pivotal trials, while expanding the Phase II trials of its other one. (BioWorld Today)
